Something that may be overlooked in the European Commission’s package of proposals for revising the EU pharmaceutical legislation is a new set of measures targeted specifically at small and medium-sized enterprises (SMEs) and not-for-profit entities.
SMEs have long been seen as an important pillar of the pharmaceutical industry in Europe as often “they are the ones developing the most innovative medicines because they take the risks when sometimes the bigger ones do not,”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?